je.st
news
Tag: iii
Sercos III Open Source Soft-Master Core Announced
2015-04-30 12:31:11| Industrial Newsroom - All News for Today
Sercos International has announced that in cooperation with Bosch Rexroth a Sercos III Soft-Master core will be provided as open source software. By using a Sercos III Soft-Master, a Sercos III master device can be implemented without specific FPGAs or ASIC Sercos III hardware controller. Instead, a standard...
Tags: open
source
iii
open source
Cavium Delivers Optimized OpenWRT on OCTEON III to Accelerate Retail/SMB Router Time to Market
2015-04-29 12:31:13| Industrial Newsroom - All News for Today
Bringing Enterprise-level Performance, Functionality and Integrated Security to Retail/SMB Routers SAN JOSE, Calif. - Cavium, Inc., (NASDAQ: CAVM), a leading provider of semiconductor products that enable intelligent processing for enterprise, data center, wired and wireless networking today announced that it has...
Norte III Combined Cycle Power Plant, Chihuahua
2015-04-29 01:00:00| Power Technology
The 924MW Norte III combined cycle power plant located approximately 30km south of the US-Mexico border in the municipality of Juárez, Chihuahua, will be the biggest combined cycle plant in Mexico upon completion.
Tags: power
iii
combined
plant
Treyarch: Black Ops III More Ambitious Than World at War
2015-04-28 02:55:07| TechNewsWorld
Activision on Monday announced the launch date for Call of Duty: Black Ops III -- Friday, Nov. 6. The company is departing from its tradition of Tuesday releases. Instead of conflicting with school and work schedules, the Friday release will give players the weekend to dive into the sci-fi shooter and get a feel for the new gameplay mechanics.
Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
2015-04-14 19:30:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & AMES, Iowa rVSV-ZEBOV-GP (V920) Now Being Studied in Three Key Safety and Efficacy Clinical Trials KENILWORTH, N.J. & AMES, Iowa--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public Health Agency of Canadas National Microbiology Laboratory and licensed to NewLink Genetics in 2010. On Nov. Language: English Contact: Merck Media:Pam Eisele, 267-305-3558orImraan Munshi, 215-652-0059Investor:NewLink Genetics:Jack Henneman, 515-598-2561orMerck:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NLNK Exchange: NASDAQ read more
Sites : [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] next »